ETF investing, Portfolio Strategy, Long/Short Equity
Contributor Since 2007
AACC Rally May Be Tepid This Year-Choppy Market in Clinical Diagnostic Stocks
The AACC Meeting in Chicago this year is usually a time of strength for clinical diagnostic stocks. But after a four year bull market and some recent earnings disappointments the market is missing upside news. Position your portfolio toward a strong Q4 finish and raise cash this summer. Q3 revenues and earnings are seasonally weak. As always we recommend a portfolio of biotech stocks or an ETF/Fund if you are not following the companies. Here is an overview of our Dx and Tools Portfolio and be sure to look at May 22 historical prices and results after Q1 correction.
We will look for news and moves this week during the AACC and update this post. At this time we do not see any need to add positions but technicals and financial strength are evident in ABAX, HOLX, ILMN and TMO. Here is the July 3 performance summary since inception.
Disclosure: The author is long HOLX, RHHBY, PACB.
Additional disclosure: we are short a few of dx stocks on a day to day level as a hedge